Ripple Therapeutics Corporation

Matthew Alexander John Statham

Ian Charles Parrag

Wendy Alison Naimark

Kyle Giovanni Battiston

Hans Christian Fischer

Dimitra Louka

J Paul Santerre

Leonard Pinchuk

Boris Gorin

Roseita Esfand

Bahareh Khalili

Georgios Rizis

Emma-Louise Elizabeth Moore

Judith Anne Williams

Elizabeth Poloz

The disclosure features polymorphs of a prodrug dimer of dexamethasone linked at the 21-C and 21'-C carbons via a carbonate-triethylene glycol-carbonate linker. Also disclosed are pharmaceutical compositions and articles comprising said polymorphs, and the use thereof in the treatment of a disease or condition, e.g. via the extended or controlled release of dexamethasone from said articles.

Crystalline forms of dexamethasone dimers and uses thereof

The disclosure relates to compounds and compositions for sustained release of ocular therapeutics.

Ocular inserts comprising a covalently linked steroid dimer

Described herein are processable compositions comprising at least one moiety that is processable in its free form. Also described herein are compositions and methods for the treatment of ocular diseases or disorders including glaucoma, blepharitis, ocular inflammation, diabetic macular edema, posterior inflammation, anterior inflammation, macular degeneration (e.g., wet macular degeneration (AMD) or dry AMD), post-cataract surgery, and retinal vein occlusion. Said compositions and methods comprise steroids and prostaglandins which demonstrate anti-inflammatory activity, intraocular pressure (IOP) lowering, and/or other desirable activities. Injection of said compositions in the eye provides therapeutic benefit to patients suffering from ocular disorders.

Heterodimer compositions and methods for the treatment of ocular disorders

The disclosure features dexamethasone prodrug dimers of dexamethasone and pharmaceutical compositions thereof useful for, e.g., the extended release of a drug and for the treatment of a disease or condition.

Dexamethasone prodrug compositions and uses thereof

The disclosure features pharmaceutical compositions formed from prodrug dimers for the extended delivery of a drug and for the treatment of a disease or condition.

Glass formulations and uses thereof

Growing community of inventors

Milton, Canada

Matthew Alexander John Statham